Today’s AI Top Pick: ALNY

Alnylam Pharmaceuticals is the cleanest 'buy the dip on a passing screen' setup in this pool. The 4h tape puts price at pos_in_21bar_range_pct = 0 with a -25.67% drawdown from the 21-bar high — you are literally NOT chasing — while the 4h forecast stack is the most aggressive in the entire list (short +63.43%, mid +61.08%, long +65.53%). The 1d timeframe confirms rather than contradicts: pos 49.81% (mid-range, healthy), dd -8.03%, and forecast ladder of +13.97% / +41.42% / +32.29%. Near_term_bullish reads 1.0 and kronos bullish_prob is 1.0 — the model is unambiguous. The fundamentals under the hood are elite for a name this beaten up: ROE 100.7%, sales YoY +95.14%, profit margin 16.82%, PEG 0.33 (cheapest growth in the group), recom 1.62, targetUpside +50.5%, institutional ownership 100.73%. This is a company growing revenue near triple-digits trading at a PEG below Netflix and Futu, with analyst support intact. The -46.93% one-year and -37.46% YTD performance are the source of the drawdown, not a broken business — Jefferies just reiterated positive (Sep 8), and there are no dilution, guidance-cut, or regulatory landmines in the recent tape. Why today, not later: the 4h just printed the bottom of its 21-bar range with a probability-1 bullish read and >60% mean-reversion forecast across every horizon. Waiting for confirmation typically costs 3-5% of the base move on names with this drawdown profile. The weekly timeframe is soft (-9.93% long), so this is a swing setup (weeks to a couple of months), not a multi-quarter hold — size accordingly. Why not the alternates: FUTU has stronger valuation (fwdPE 8.95) and 0.8 near-term bullish, but sits at pos_in_21bar_range = 100 on the 4h with a materially negative weekly forecast (-29.91% long) — chasing risk. WAY has great analyst support (recom 1.16) but 4h is at pos 94.73 and near-term bullish is only 0.4. TIGR/PSIX print outlier 4h forecasts (+79% / +51%) that scream single-bar anomaly, and PSIX's weekly is deeply negative (-51.89% long).